コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 PVL and LukGH have potent cytolytic activity in vitro, a
2 PVL enhanced the capacity of USA300 to cause severe lung
3 PVL enhanced the virulence of a subset of MRSA strains i
4 PVL expression augmented the cytotoxicity of S. aureus o
5 PVL genes are consistently associated with skin and soft
6 PVL improved postprocedure (P<0.001) and was none (33.3%
7 PVL is capable of lysing human white blood cells, but at
8 PVL is thought to play a key role in the pathogenesis of
9 PVL production ranged from 0.02 to 4.865 mug/ml and corr
10 PVL strains are strongly associated with skin and soft-t
11 PVL was significantly reduced in L-treated mice compared
12 PVL was the predominant factor determining late-stage bo
13 PVL-positive (PVL(+)) S. aureus was frequent in the lesi
14 PVL-positive skin and soft-tissue infections are more li
15 PVL-treated mice were subjected to splenic, renal, or pu
16 accine was associated with lower ATI week 16 PVL even after controlling for viral and host genetic fa
17 RSA isolates, we identified 30 spa types, 47 PVL-negative and 15 scn-negative isolates, and no ST398
20 riventricular neural apoptosis resulted in a PVL-like phenotype that recapitulates the primary perive
22 ate odds of infection or colonisation with a PVL-positive strain with fixed-effects or random-effects
25 s with the gp120 outer domain, including all PVL signature and CD4 mimicry interactions, but not crit
28 white blood cells, but at sublytic amounts, PVL can activate protective host immunity in the absence
29 rginine catabolic mobile element (ACME), and PVL-carrying prophage, PhiSa2 or PhiSa2-like regions on
31 e at separate sites with isogenic PVL(+) and PVL(-) MRSA abrogated the differences in bacterial burde
34 model that explains how influenza virus and PVL act together to cause necrotizing pneumonia: an infl
36 ted transient increases in anti-Hla and anti-PVL antibodies; however, subsequent infection risk was s
38 ore likely to be treated surgically than are PVL-negative infections, and children with PVL-positive
41 L-positive, methicillin-resistant S. aureus (PVL-MRSA) strains, although three novel spa types and a
42 methicillin-resistant Staphylococcus aureus (PVL-MRSA) in adult patients who were screened systematic
47 recruited neutrophils are rapidly killed by PVL, resulting in uncontrolled release of neutrophil pro
49 model systems identified the same candidate (PVL 10) as the most active promoter of vasopermeation in
50 e were no VISA or VRSA isolates that carried PVL genes or ACME, and most strains (69.8%) were staphyl
51 l phage insertion sites in 52 S. aureus CC30 PVL-harboring isolates, collected from four continents o
52 d with community-onset-PVL-negative MRSA (CO-PVL-negative MRSA vs. all other MRSA), with adjusted odd
54 -knockout mutant (Deltapvl) and complemented PVL-positive derivative, to evaluate the role of PVL in
55 genic Deltapvl strains and further confirmed PVL's capacity to activate proinflammatory responses fro
59 e of TDR mutations increased with decreasing PVL (rate ratio [RR], 0.91 per 1000 decrease in PVL; P =
61 o PVL and then infected with seven different PVL(+) strains also had significantly higher bacterial c
62 that, independent of its cytotoxic effects, PVL also plays an important and positive immunomodulator
64 or design of immunogens capable of eliciting PVL antibodies is that VH1-2*02 germ-line BCR interactio
68 c resection performing surgical exploration, PVL, and ISS results in a marked and rapid hypertrophy o
73 teracts this pathogen strategy by generating PVL-neutralizing antibodies and by neutralizing the rele
75 0 copies/mL) was closely associated with HIV PVL (beta = 0.51 per log10 copies/ml increase, 95%CI:0.4
76 hat higher antibody levels against Hla, Hld, PVL, SEC-1, and PSM-alpha3 may protect against sepsis in
77 vascular disease, diabetes, SCCmec type II, PVL negativity, and higher vancomycin MIC (all P values
80 The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained inc
81 -MSSA identical to those previously found in PVL-MRSA isolates highlights the role these strains may
82 he detection of PVL phages and haplotypes in PVL-MSSA identical to those previously found in PVL-MRSA
85 sent for K103N (RR, 1.00 per 100 increase in PVL; P = .99) and negative for L90M (RR, 0.75 per 100 in
89 ular foci, including the subplate region, in PVL, and may contribute to abnormal cortical formation a
93 train from Taiwan, together with an isogenic PVL-knockout mutant (Deltapvl) and complemented PVL-posi
96 ld-type parental USA300 strain, the isogenic PVL deletion-mutant strain caused equivalent lower respi
97 tion of mice at separate sites with isogenic PVL(+) and PVL(-) MRSA abrogated the differences in bact
100 f prosthetic mitral valve paravalvular leak (PVL) has emerged as an alternative to surgical treatment
103 Significant prosthetic paravalvular leakage (PVL) could have serious clinical consequences and impair
104 SCCmec) typing, Panton-Valentine leucocidin (PVL) screening, and pulsed field gel electrophoresis (PF
106 t currently for Panton-Valentine leucocidin (PVL)-positive, methicillin-sensitive Staphylococcus aure
107 and HlgCB) and Panton-Valentine leukocidin (PVL or LukSF) were shown to assemble from soluble subuni
109 xins, including Panton-Valentine leukocidin (PVL) and alpha-hemolysin (Hla), although supporting evid
110 ns were USA300, Panton-Valentine leukocidin (PVL) and arginine catabolic mobile element (ACME) positi
112 ains expressing Panton-Valentine leukocidin (PVL) are associated with severe skin and soft tissue inf
113 The lukF/lukS Panton-Valentine leukocidin (PVL) genes did not directly correlate with the ISS, bein
114 n, detection of Panton-Valentine leukocidin (PVL) genes, arginine catabolic mobile element (ACME), an
115 assays for the Panton-Valentine leukocidin (PVL) genes, the protein A gene (spa), and arcA and opp3,
119 S. aureus toxin Panton-Valentine leukocidin (PVL) is most likely causative for necrotizing diseases,
121 The impact of Panton-Valentine leukocidin (PVL) on the outcome in Staphylococcus aureus pneumonia i
123 re subjected to Panton-Valentine leukocidin (PVL) screening, and SCCmec, pulsed-field gel electrophor
126 ains, expresses Panton-Valentine leukocidin (PVL), a pore-forming toxin that targets polymorphonuclea
128 element (ACME), Panton-Valentine leukocidin (PVL), and other toxins that may contribute to disease se
129 strains produce Panton-Valentine leukocidin (PVL), but its contribution to CA-MRSA pathogenesis is po
132 xins, including Panton-Valentine leukocidin (PVL), leukotoxin GH (LukGH; also known as LukAB), leukot
133 characteristics Panton-Valentine leukocidin (PVL), SCCmec IVa, the arginine catabolic mobile element
134 emolysin (Hld), Panton Valentine leukocidin (PVL), staphylococcal enterotoxin C-1 (SEC-1), and phenol
137 USA300 and its Panton-Valentine leukocidin (PVL)- and alpha-hemolysin (Hla)-negative isogenic deriva
141 lysin (Hla) and Panton-Valentine leukocidin (PVL; LukF-PV/LukS-PV subunits), both premier targets of
143 disease (HD), periventricular leukomalacia (PVL), and kidney dysfunction; Fer-1 inhibited lipid pero
144 ogies, notably periventricular leukomalacia (PVL), which is distinguished by bilateral necrosis of ne
148 cal exploration, right portal vein ligation (PVL), and in situ splitting (ISS) of the liver parenchym
149 of signature features for potent VRC01-like (PVL) antibodies, and verify the importance of these feat
151 of TDR mutations and population viral load (PVL) among treated patients during 1997-2011 was estimat
152 tal HIV shedding with HIV plasma viral load (PVL), herpetic lesions, HSV shedding and other factors w
153 to determine the distribution of lysogenized PVL phages among MRSA strains with PVL (PVL-MRSA strains
154 mL), and 77 (72%) were viremic with a median PVL of 5450 copies/mL (interquartile range, 169-1 997 96
157 e patients who underwent percutaneous mitral PVL closure at Mayo Clinic, Rochester, MN, between Janua
158 t of patients undergoing percutaneous mitral PVL closure, successful percutaneous reduction of the PV
163 fferent mammalian species, where activity of PVL is found to be restricted to fewer species than that
164 hitherto unrecognized low-level carriage of PVL-CSMRSA among patients being admitted to hospitals in
167 es in 114 isolates comprising nine clones of PVL-MRSA that were selected for maximal underlying genet
178 um skin infection model, where low levels of PVL augmented innate immune resistance to infection.
180 dings provide insights into the mechanism of PVL-induced lung injury and inflammation and demonstrate
181 es, but the precise pathogenic mechanisms of PVL and a possible contribution of influenza virus remai
182 rtant insights into the microepidemiology of PVL-harboring CC30 strains, while the discovery of PhiSa
183 rtant insights into the microepidemiology of PVL-MRSA, will prove a valuable adjunct in outbreak inve
188 riginal research reporting the prevalence of PVL genes among Staphylococcus aureus pneumonia, bactera
189 l counts, suppressed bacterial production of PVL and Hla, and reduced production of the neutrophil-ch
192 man corneal epithelial cells and the role of PVL and antibody to PVL in pathogenesis of murine kerati
194 sed studies are needed to define the role of PVL in mild, moderate, and severe disease and to inform
195 positive derivative, to evaluate the role of PVL in the pathogenesis of CA-MRSA in the RHEK-1 human k
197 es the temporal and spatial specificities of PVL and indicate that damage to VEGF-dependent, immature
200 vation of PMNs, indicating that virulence of PVL(+) MRSA is enhanced by the interference of PVL-activ
201 e positively associated with community-onset-PVL-negative MRSA (CO-PVL-negative MRSA vs. all other MR
212 ermined here the distribution of PVL phages, PVL gene sequences, and chromosomal phage insertion site
214 he CC8/Panton-Valentine leukocidin-positive (PVL(+)) group of S. aureus clone USA300: 34 of these str
218 toxins Panton-Valentine leukocidin LukSF-PV (PVL) and gamma-hemolysin CB (HlgCB) target human phagocy
219 ized PVL phages among MRSA strains with PVL (PVL-MRSA strains), the PVL gene sequences, and the chrom
220 ity of methods for assessing and quantifying PVL, and lack of consistency in the timing of such asses
222 residual PVL, patients with </=mild residual PVL had lower rates of repeat surgical interventions (6%
223 Compared with those who had >mild residual PVL, patients with </=mild residual PVL had lower rates
231 rgeons score 7+/-4%) with severe symptomatic PVL in mitral (81%) or aortic (19%) position underwent t
232 alence, progression, and impact of post-TAVR PVL and to help direct future efforts regarding the asse
233 ffect of antibody treatment, it appears that PVL plays an inconsistent role in pathogenesis and immun
236 ns with their receptors, we demonstrate that PVL and HlgCB differentially interact with human C5aR1 a
238 onia and used it to test the hypothesis that PVL contributes to lower respiratory tract infections ca
239 model in rabbits to test the hypothesis that PVL contributes to USA300 pathogenesis and compare it wi
244 low doses induced apoptosis, suggesting that PVL also has the capacity to regulate inflammation.
245 oversial, with clinical data suggesting that PVL-producing strains may cause less severe disease in h
248 sular polysaccharide gene cap5E Although the PVL-encoding phage varphiSa2USA was introduced into the
249 resence of SCCmec type IV, the ACME, and the PVL toxin gene and matched the t008 or t121 molecular sp
251 , lineage-specific relationships between the PVL phage, the genes that encode the toxin, and the posi
253 egions was 54 to 80% lower (p</=0.01) in the PVL cases (n=15) compared to controls adjusted for age a
256 nce of the arcA gene and the presence of the PVL genes (area under the curve, 0.980; 95% confidence i
257 re, successful percutaneous reduction of the PVL to mild or less was associated with significant midt
258 RSA strains with PVL (PVL-MRSA strains), the PVL gene sequences, and the chromosomal phage insertion
259 ion M184V was positively associated with the PVL of nonresponding patients carrying M184V (RR, 1.50 p
260 VL included lower pre-antiretroviral therapy PVL, greater Gag sequence divergence from the vaccine se
261 ons in humans, it appears that antibodies to PVL might contribute to host susceptibility to infection
263 ght possibly be neutralized by antibodies to PVL, which are found in normal human sera and at increas
268 opical treatment with polyclonal antibody to PVL yielded significant reductions in corneal pathology
271 PMNs are less susceptible than human PMNs to PVL-induced cytolysis, whereas rabbit PMNs, like those o
272 emnant liver after ALPPS doubled relative to PVL, whereas mice with transection alone disclosed minim
274 in this study showed a genetic similarity to PVL-positive, methicillin-resistant S. aureus (PVL-MRSA)
277 cC, vanA, Panton-Valentine Leukocidin toxin (PVL), and toxic shock syndrome toxin-1 (tst) genes.
280 ecutive patients who underwent transcatheter PVL closure in our center were prospectively enrolled.
283 We hypothesized that a key to understanding PVL's action on host cells and, possibly, outcomes from
285 clude routine detection of genes for USA300, PVL, or mupA, all of which were either of low frequency
288 tors independently associated with lower w16 PVL included lower pre-antiretroviral therapy PVL, great
290 cA-positive MRSA isolates, five (14.7%) were PVL-positive, seventeen (50%) were tst-positive, ten (29
294 om nontemperate climates are associated with PVL(+) S. aureus and promote the emergence and spread of
295 e PVL-negative infections, and children with PVL-positive musculoskeletal disease might have increase
296 Circulating factors in combination with PVL seem to mediate enhanced liver regeneration, associa
298 d odds ratios (ORs) to compare patients with PVL-positive colonisation and each infection relative to
299 sogenized PVL phages among MRSA strains with PVL (PVL-MRSA strains), the PVL gene sequences, and the
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。